Technical Information

InertSearch (Application Library)

Index

Application

Micro GC

Document No. Index

LB201 - 300 of Application List

No. Description Column
LB201 Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-3
LB202 Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) Inertsil ODS-3
LB203 Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) Inertsil ODS-3
LB204 Analysis of Metformin hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Metformin hydrochloride Tablets) InertSustain C18
LB205 Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Paroxetine hydrochloride Tablets) Inertsil TMS
LB206 Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) Inertsil TMS
LB207 Analysis of Montelukast sodium InertSustain Phenyl
LB208 Analysis of Montelukast sodium (Oxidative degradation products) InertSustain Phenyl
LB209 Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB210 Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB211 Analysis of 2 kinds of Aldehydes (InertSustain C18) (Directed by Pre-Column Method with DNPH) InertSustain C18
LB212 Analysis of 2 kinds of Aldehydes (Inersil ODS-4) (Directed by Pre-Column Method with DNPH) Inertsil ODS-4
LB213 Analysis of 2 kinds of Aldehydes (Inersil ODS-3) (Directed by Pre-Column Method with DNPH) Inertsil ODS-3
LB214 Analysis of 2 kinds of Aldehydes (Inersil ODS-2) (Directed by Pre-Column Method with DNPH) Inertsil ODS-2
LB215 Analysis of 2 kinds of Aldehydes (Inersil ODS) (Directed by Pre-Column Method with DNPH) Inertsil ODS
LB216 Analysis of 2 kinds of Aldehydes (Inersil ODS-SP) (Directed by Pre-Column Method with DNPH) Inertsil ODS-SP
LB217 Analysis of 2 kinds of Aldehydes (Inersil ODS-P) (Directed by Pre-Column Method with DNPH) Inertsil ODS-P
LB218 Analysis of Diquat and Paraquat Inertsil WP300 SIL
LB219 Analysis of Amino acid (post-column ninhydrin) # 2619PH
LB220 Analysis of Amino acid (post-column OPA) # 2619PH
LB221 Analysis of Glutamic acid (post-column ninhydrin) # 2619PH
LB222 Analysis of Butenafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18 HP
LB223 Analysis of Cilnidipine (Under the Condition of the Japanese Pharmacopoeia, Cilnidipine Tablets) Inertsil ODS-4
LB224 Analysis of Tocopherol (InertSuatin C18) (Under the Condition of the Japanese Pharmaceutical Codex) InertSustain C18
LB225 Analysis of Tocopherol (Inertsil ODS-4) Inertsil ODS-4
LB226 Analysis of Tocopherol (Inertsil ODS-3) Inertsil ODS-3
LB227 Analysis of Tocopherol (Inertsil ODS-2) Inertsil ODS-2
LB228 Analysis of Polyvinyl alcohol, Polyethyleneglycol and Graft copolymer (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), (3) Acetic acid) InertSustain C18
LB230 Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) InertSustainSwift C18 HP
LB231 Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) InertSustainSwift C18 HP
LB232 Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) InertSustainSwift C18 HP
LB233 Analysis of Amino acids InertSustainSwift C18
LB234 Analysis of Amino acids InertSustainSwift C18
LB235 Analysis of Preservatives and Sweetener (InertSustain Phenylhexyl) InertSustain Phenylhexyl
LB236 Analysis of Preservatives and Sweetener (InertSustainSwift C18) InertSustainSwift C18
LB237 Analysis of Preservatives and Sweetener (InertSustain C18) InertSustain C18
LB238 Analysis of Preservatives and Sweetener (InertSustain Phenylhexyl) InertSustain Phenylhexyl
LB239 Analysis of Preservatives and Sweetener (InertSustainSwift C18) InertSustainSwift C18
LB240 Analysis of Preservatives and Sweetener (InertSustain Phenyl) InertSustain Phenyl
LB241 Analysis of Preservatives and Sweetener (InertSustain C18) InertSustain C18
LB242 Analysis of Preservatives and Sweetener (Inertsil Ph) Inertsil Ph
LB243 Analysis of Acarbose (Under the Condition of the Japanese Pharmacopoeia, Acarbose Tablets) Inertsil WP300 C18
LB245 Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) Inertsil ODS-4
LB246 Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) Inertsil ODS-4
LB247 Analysis of Terbinafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Terbinafine hydrochloride Cream) InertSustainSwift C18
LB248 Analysis of Organic electroluminescence materials Inertsil ODS-3V
LB249 Analysis of Organic electroluminescence materials Inertsil ODS-3V
LB250 Analysis of Azelnidipine (Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-4
LB251 Analysis of Quetiapine fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine fumarate Tablets) Inertsil C8-4
LB252 Analysis of Glimepiride Inertsil Diol
LB253 Analysis of Tranilast (Under the Condition of the Japanese Pharmacopoeia, Tranilast Capsules) InertSustain C18
LB254 Analysis of Brotizolam (Under the Condition of the Japanese Pharmacopoeia, Brotizolam Tablets) Inertsil WP300 C18
LB255 Analysis of Pullulan Inertsil WP300 Diol + Inertsil Diol
LB256 Analysis of Nucleobase (InertSustain C18) InertSustain C18
LB257 Analysis of Nucleobase (InertSustain Phenyl) InertSustain Phenyl
LB258 Analysis of Tetracyclines InertSustain C18
LB259 Analysis of Tryptic digest of proteins MonoCap C18 High Resolution 2000
LB260 Analysis of Chlorophenol InertSustain C18 HP
LB261 Analysis of 18 Drugs Inertsil ODS-3
LB262 Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) InertSustain C8
LB263 Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) Inertsil C8-3
LB264 Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) Inertsil C8-3
LB265 Analysis of Tacrolimus (Under the Condition of the Japanese Pharmacopoeia, Tacrolimus Capsules) Inertsil ODS-2
LB267 Analysis of D-Mannitol HC-75(Ca+)
LB268 Analysis of Tetracyclines (InertSustain C18) InertSustain C18
LB269 Analysis of Tetracyclines (InertSustainSwift C18) InertSustainSwift C18
LB270 Analysis of β-blocker InertSustainSwift C18
LB271 Analysis of Tulathromycin InertSustainSwift C18
LB272 Analysis of Ibuprofen and Indometacin InertSustain Phenylhexyl
LB273 Analysis of Vitamin B InertSustain Phenylhexyl
LB274 Analysis of Capsaicin InertSustain Phenylhexyl
LB275 Analysis of Histamine antagonist InertSustain Phenylhexyl
LB276 Analysis of Anti-depressant drugs InertSustain Phenylhexyl
LB277 Analysis of β-blocker InertSustain Phenylhexyl
LB278 Analysis of Calcium antagonist InertSustain Phenylhexyl
LB279 Analysis of Indometacin (Under the Condition of European Pharmacopoeia 8.2) InertSustain Phenylhexyl
LB281 Analysis of Montelukast sodium (Inertsil Ph) (Under the Condition of the Japanese Pharmacopoeia, Montelukast sodium Tablets) Inertsil Ph
LB282 Analysis of Povidone (Under the Condition of the Japanese Pharmacopoeia 16th edition, (4) 1-Vinyl-2-pyrrolidone) InertSustain C8
LB283 Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB284 Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB285 Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-4 HP
LB286 Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-4 HP
LB287 Analysis of Sugar Spheres (Under the Condition of USP 37-NF32) Inertsil NH2
LB289 Analysis of Aflatoxin InertSustain C18
LB290 Analysis of Cefalexin (Under the Condition of the Japanese Pharmacopoeia, Cefalexin Combination Granules) InertSustain C18
LB291 Analysis of Ticlopidine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Ticlopidine hydrochloride Tablets) InertSustain C18
LB294 Analysis of Montelukast sodium InertSustain Phenylhexyl
LB295 Analysis of Irbesartan (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB297 Peptide Separation of Casein Tryptic Digests by Preparative HPLC ODS Column (20 mm I.D.) Inertsil ODS-3
LB298 Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) Inertsil WP300 C18
LB299 Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-3
LB300 Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil WP300 C18